Αρχική Uncategorized Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer Survival,...

Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer Survival, Study Says

It comes as no surprise that timely treatment is an important factor in the survivability of breast cancer. However, you may be a bit more surprised to hear that getting done with treatment quickly can also promote survival.

Researchers at the Cleveland Clinic and Cleveland Clinic Abu Dhabi found that there was a notable increase in patient survival rates when all the patients’ treatments, regardless of which types of treatments are used, are completed within 38 weeks from the date of diagnosis.

The study involved more than 28,000 breast cancer patients, all of whom were registered in the American National Cancer Database. Researchers measured the five-year survival of each patient and found that 89.9 percent survived for at least five years when their treatment time was less than 38 weeks, compared to 83.3 percent survival among patients whose treatment took longer than 38 weeks to complete.

Photo: Adobe Stock/Africa Studio

Article continues below

Our Featured Programs

See how we’re making a difference for People, Pets, and the Planet and how you can get involved!

Previous studies have established poorer outcomes and less survivability among patients who experience a delay between their diagnosis and their first treatment. For example, the time between diagnosis and the first surgical treatment should be less than 90 days, and the time to first adjuvant chemotherapy should be less than 120 days. However, this is the first study to establish a change in survival rates based on the time it takes for treatments to be concluded.

“The biggest difference in our study from others that have looked at time to treat was that we looked at the time from diagnosis to the completion of the multimodality treatment, not only at one individual part, to identify the 38-week window to improve survival rate for patients with breast cancer,” says Debra Pratt, M.D., director of the Breast Center at Cleveland Clinic Fairview Hospital and the lead author of the study.

Photo: Adobe Stock/Monkey Business

In breast and other cancers, patients don’t only get surgery, but may also require chemotherapy and radiation therapy,” Dr. Pratt continues. “This becomes a complicated system to navigate and there are multiple reasons why delays arise in treatment being completed. This analysis helps us identify opportunities for improving care within the delivery systems.”

The researchers say their study demonstrates that optimal treatment completion times are actually shorter than the currently recommended completion times.

“What we found is that the optimal time for treatment completion is 99 days shorter than C3PR quality indicators,” Dr. Pratt says. “We have so much more data now to reassess these quality indicators and determine what those metrics should be.”

Photo: Adobe Stock/tippapatt

The authors of the study recommend that healthcare systems take a careful look at when and why delays in the treatment process are occurring and work on minimizing them. There are often valid medical, personal, and systemic reasons for delaying treatments, but decreasing delays and shortening treatment times could greatly improve outcomes for patients. Adequate staffing, reduction in insurance delays, and other improved systems that increase ease of access could help achieve this goal.

“What we see happen traditionally in the U.S. and even in the U.A.E. is that the patient has to visit multiple specialists – first a surgeon, then a medical oncologist for chemotherapy followed by a radiation oncologist – all of which are scheduled weeks apart and in different places,” says Stephen Grobmyer, M.D., chair of the Oncology Institute at Cleveland Clinic Abu Dhabi, an integral part of Mubadala Health, and a co-author on the study. “There is this phenomenon of ‘serial care,’ rather than coordinated and planned care.”

Further studies should look into which treatment types result in the greatest delays and what could be changed to minimize those delays.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...